In the same way that provision of ART led to massive cost savings in terms of avoided hospitalisations and opportunistic infections [29], the cost savings made by delaying ART initiation are at least partly offset by the cost of treating opportunistic infections among those who present sick (with low CD4). The gene discussed is CD4; the disease is Opportunistic infection.